China, October 2, 2026
Abogen Biosciences has announced a major licensing and option agreement with Novartis to advance innovative mRNA-encoded therapeutics, marking a significant business and scientific milestone for the clinical-stage biotechnology company. The agreement includes an exclusive worldwide license to ABO2203, Abogen’s lead mRNA-encoded CD19xCD3 T-cell engager, along with exclusive options for Novartis to license additional therapeutic programs developed using Abogen’s proprietary RNA platform. Under the proposed agreement, Abogen will receive an upfront payment of $575 million and could receive up to approximately $7.2 billion in potential milestone payments if all options are exercised and specified development, regulatory, and commercial milestones are achieved.
Novartis Gains Global Rights to ABO2203
At the center of the agreement is ABO2203, a novel mRNA-encoded CD19xCD3 T-cell engager being developed for potential treatment of B-cell-mediated autoimmune diseases. Unlike conventional recombinant T-cell engagers, ABO2203 is designed to use mRNA technology to direct the body’s own cells to produce T-cell engagers in vivo. The approach is intended to enable targeted B-cell depletion and potentially provide a differentiated method for achieving immune reset in autoimmune disorders. Abogen describes ABO2203 as the first mRNA-encoded T-cell engager to enter clinical evaluation for autoimmune diseases, highlighting the novel nature of the program. The CD19xCD3 design brings together two biological targets: CD19, a marker expressed on B cells, and CD3, a component of T cells. By engaging these targets, the therapeutic strategy is intended to bring T cells into contact with B cells and promote targeted B-cell depletion. B cells play important roles in the development of several autoimmune diseases, making B-cell-directed approaches an active area of pharmaceutical research. Abogen’s mRNA-based approach seeks to generate the therapeutic molecule inside the body, rather than administering a conventionally manufactured protein directly.
Abogen Expands Proprietary RNA Platform
The agreement extends beyond ABO2203, with Novartis receiving exclusive options to license additional potential therapeutic programs developed using Abogen’s proprietary RNA platform. The platform is designed to support the discovery and development of mRNA-based medicines and incorporates AI-driven and automation-enabled technologies covering mRNA design, formulation development, and large-scale GMP manufacturing. Abogen has built a pipeline spanning oncology, autoimmune diseases, and prophylactic vaccines. Its lead vaccine candidate, ABO1108, is a lyophilized mRNA shingles vaccine currently undergoing Phase 3 clinical trials in China. The company says the Novartis agreement demonstrates the potential of its RNA technology to expand beyond its earlier focus on prophylactic vaccines toward a broader range of therapeutic applications.
Advertisement
$575 Million Upfront and Potential $7.2 Billion Milestones
Financially, the agreement represents a significant transaction for Abogen. The company will receive a $575 million upfront payment, while the potential milestone value could reach approximately $7.2 billion if Novartis exercises all available options and the relevant programs achieve agreed development, regulatory, and commercial milestones. Abogen may also receive royalties on future product sales. The transaction remains subject to customary closing conditions, including required regulatory clearances, meaning the announced agreement does not yet represent completion of the transaction. The potential milestone payments are also contingent on future achievements and should not be interpreted as guaranteed revenue.
The collaboration highlights growing pharmaceutical interest in mRNA technology beyond vaccines, particularly for therapeutic applications involving cancer and immune-mediated diseases. By combining Abogen’s RNA discovery and manufacturing capabilities with Novartis’ global development and commercialization expertise, the agreement could accelerate the development of mRNA-encoded immune therapies. For the broader biopharmaceutical sector, the deal underscores the expanding potential of RNA platforms, in vivo protein production, and next-generation T-cell engager technologies in drug development.
Source: Abogen Biosciences, Novartis press release
